Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer

Paolo Pronzato, Antonella Vigani, Floriana Pensa, Maurizio Vanoli, Francesco Tani, Franco Vaira

Research output: Contribution to journalArticlepeer-review

Abstract

We have carried out a phase II study in advanced or metastatic transitional cell carcinoma of the bladder. Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy. Treatment consisted of ifosfamide 1000 mg/sm in a 2-hour infusion for 5 consecutive days from d.1 to d.5. Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion. Twenty patients entered the study and received a total of 62 cycles: the treatment resulted feasible on an outpatient basis, with mild toxicity. Only one partial response was observed. With this dose and schedule, ifosfamide appeared less effective than in a previous report at higher doses. Toxicity was acceptable.

Original languageEnglish
Pages (from-to)519-521
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number5
DOIs
Publication statusPublished - Oct 1997

Keywords

  • Ifosfamide
  • Mesna
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer'. Together they form a unique fingerprint.

Cite this